$4.21
+0.06 (+1.45%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where INTS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 with posted results
Held by 0 tracked-famous managers · FINRA short interest 2.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)NCT06263231Overall Survival (OS)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: INT230-6, Eribulin, Trabectedin, Pazopanib | Sarcoma,Soft Tissue | 333 | Dec 2027 | ≤ 499 d | 2026-08-11 |
| A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6NCT03058289results2024-08-13Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: INT230-6 · Biological: anti-PD-1 antibody, anti-CTLA-4 antibody | Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma | 111 | 2023-02-22actual | — | 2025-02-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19